Galapagos is a clinical stage biotech company focused on developing novel medicines.  Headquartered in Belgium, the Company employs around 800 people and reported 2012 revenues of €153 million.

Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.

• Learn more about GLPG0634’s selective JAK1 profile
• View the EULAR 2012 presentation for GLPG0634
• View the ACR presentation for GLPG0634
• View the ACR poster for GLPG0634
• Interview with Dr. Frédéric Vanhoutte: GLPG0634 Proof of Concept results
• Click here to access the Full Year Results 2012 audio webcast
• Click here to access the R&D Update audio webcast, or view the presentation or transcript
• View the ASPET presentation for GLPG0974